To translate this application to the clinic, a Phase I/II clinical trial is testing the safety and efficiency of TILs transduced with CXCR2 in treating patients with stage III melanoma and metastatic melanoma (NCT01740557). The gene discussed is CXCR2; the disease is melanoma.